# OnCo record sclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/sclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "sclc" ;
  schema:name "Small-cell lung cancer"@en ;
  schema:alternateName "Small cell lung carcinoma"@en, "SCLC"@en, "Oat cell carcinoma"@en, "Small cell carcinoma of the lung"@en ;
  schema:description "A fast-growing lung cancer. About a third of cases are confined to one side of the chest and are treated to cure with chemotherapy and radiotherapy together; the rest respond to chemotherapy and relapse quickly. After 30 years without progress, durvalumab consolidation, the T-cell engager tarlatamab and antibody-drug conjugates have each lengthened survival since 2024."@en ;
  schema:url <https://onco.cc/cancers/sclc/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Small-cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q738170> ;
  schema:citation <https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq>, <https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462>, <https://www.nice.org.uk/guidance/ng122/chapter/Management>, <https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care>, <https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists>, <https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives>, <https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/small-cell-lung-cancer>, <https://roycastle.org/learn-about-lung-cancer/advanced-lung-cancer/>, <https://roycastle.org/learn-about-lung-cancer/living-with-cancer/>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness>, <https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://www.maggies.org/support-and-information/>, <https://doi.org/10.1056/NEJMoa1000678> ;
  onco:tag "lung" ;
  onco:related <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/lung-lcnec/>, <https://onco.cc/cancers/lung-net/>, <https://onco.cc/biomarkers/dll3-expression/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/nhs-targeted-lung-health-check/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/sstr2/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/notch1/> ;
  onco:companies <https://onco.cc/companies/epicentrx/>, <https://onco.cc/companies/genprex/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/pharmamar/>, <https://onco.cc/companies/henlius/>, <https://onco.cc/companies/bms/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/gustave-roussy/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/sclc-signalling/>, <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/notch/>, <https://onco.cc/pathways/transcription-addiction/> ;
  onco:terms <https://onco.cc/terms/limited-extensive-stage/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/pci-term/>, <https://onco.cc/terms/pack-year/>, <https://onco.cc/terms/smoking-cessation/>, <https://onco.cc/terms/tnm-9-lung-cancer/>, <https://onco.cc/terms/ebus-tbna/>, <https://onco.cc/terms/pancoast-tumour/>, <https://onco.cc/terms/superior-vena-cava-obstruction/>, <https://onco.cc/terms/malignant-pleural-effusion/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/pleural-effusion/>, <https://onco.cc/terms/pleurodesis/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/driver-mutation/> ;
  onco:trials <https://onco.cc/trials/nct07739758/>, <https://onco.cc/trials/nct06616532/>, <https://onco.cc/trials/nct06247605/>, <https://onco.cc/trials/slotman-pci-es-sclc/>, <https://onco.cc/trials/takahashi-pci/>, <https://onco.cc/trials/nct06712316/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/nct03164616/>, <https://onco.cc/trials/nct05555732/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct03178552/>, <https://onco.cc/trials/nct06561386/>, <https://onco.cc/trials/nct05984277/>, <https://onco.cc/trials/nct07513376/>, <https://onco.cc/trials/nct06077760/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct07361497/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct06767514/>, <https://onco.cc/trials/nct06726265/>, <https://onco.cc/trials/nct05920356/>, <https://onco.cc/trials/nct07361510/>, <https://onco.cc/trials/nct06417814/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/nct06216301/>, <https://onco.cc/trials/nct06687369/>, <https://onco.cc/trials/nct06500026/>, <https://onco.cc/trials/nct06838273/>, <https://onco.cc/trials/nct06758401/>, <https://onco.cc/trials/nct06382129/>, <https://onco.cc/trials/nct06801834/>, <https://onco.cc/trials/nct06128837/>, <https://onco.cc/trials/nct06899126/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct04624204/>, <https://onco.cc/trials/nct07472517/>, <https://onco.cc/trials/nct03390686/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct04923906/>, <https://onco.cc/trials/nct06712355/>, <https://onco.cc/trials/nct05654454/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct05089734/>, <https://onco.cc/trials/nct01064466/>, <https://onco.cc/trials/nct06793215/>, <https://onco.cc/trials/nct07145333/>, <https://onco.cc/trials/nct06881784/>, <https://onco.cc/trials/nct06350097/>, <https://onco.cc/trials/nct07183189/>, <https://onco.cc/trials/nct06041776/>, <https://onco.cc/trials/nct07502300/>, <https://onco.cc/trials/nct06617416/>, <https://onco.cc/trials/nct07010263/>, <https://onco.cc/trials/nct06074588/>, <https://onco.cc/trials/nct06348199/>, <https://onco.cc/trials/nct06305754/>, <https://onco.cc/trials/nct07625644/>, <https://onco.cc/trials/nct02411448/>, <https://onco.cc/trials/nct04316364/>, <https://onco.cc/trials/nct06928389/>, <https://onco.cc/trials/nct05840016/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/>, <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/>, <https://onco.cc/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/>, <https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/>, <https://onco.cc/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/>, <https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/> ;
  onco:journals <https://onco.cc/journals/clinical-lung-cancer/>, <https://onco.cc/journals/lung-cancer-journal/>, <https://onco.cc/journals/thoracic-cancer/>, <https://onco.cc/journals/chinese-journal-of-lung-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/ryz101/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/al8326/>, <https://onco.cc/drugs/tng260/>, <https://onco.cc/drugs/au-007/>, <https://onco.cc/drugs/or502/>, <https://onco.cc/trials/dellphi-305/>, <https://onco.cc/trials/ideate-lung02/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/ideas/idea-sclc-subtype-directed/>, <https://onco.cc/ideas/idea-mri-surveillance-replaces-pci/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/pairings/tarlatamab-vs-idxd-sequence/>, <https://onco.cc/pairings/chemo-io-then-maintenance-sclc/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/convert/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/imforte/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/trials/ideate-lung02/>, <https://onco.cc/drugs/ryz101/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/terms/performance-status/> .